How Are DCTs Impacting Your Clinical Sites?
Source: Life Science Leader
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
The technologies required to perform decentralized clinical trials (DCTs) and hybrid trials have been around for years. Unfortunately, many sponsor companies seemed reluctant to adopt them. That all changed in the spring of 2020 when the COVID-19 pandemic hit. Many drug developers were caught by surprise as clinics became overwhelmed with COVID patients. With the prospect of trials being delayed or canceled, DCTs and hybrid trials suddenly were the solution to keeping studies on track.
VIEW THE MAGAZINE ARTICLE! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader X
Subscribe to Life Science Leader